{
    "ticker": "CVU",
    "name": "Cleveland BioLabs, Inc.",
    "description": "Cleveland BioLabs, Inc. is a biotechnology company focused on developing innovative therapies that enhance the body's natural defenses to combat cancer and other serious medical conditions. Founded in 2006 and headquartered in Buffalo, New York, the company specializes in the research and development of drugs that harness the power of the body's immune system. Their lead product candidate, CBLB502, is designed to protect healthy tissues from the harmful effects of radiation and is being developed for various applications, including cancer therapy and biodefense. Cleveland BioLabs aims to create life-saving treatments through its proprietary technologies, including their unique compounds that target and modulate the immune response. The company collaborates with various research institutions and pharmaceutical companies to advance its products from the laboratory to clinical application. Cleveland BioLabs is committed to improving patient outcomes and quality of life through innovative medical solutions, and continues to explore new avenues for growth in the biotechnology sector.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Buffalo, New York, USA",
    "founded": "2006",
    "website": "https://www.clevelandbiolabs.com",
    "ceo": "Andrzej B. K. Kaczmarek",
    "social_media": {
        "twitter": "https://twitter.com/ClevelandBioLab",
        "linkedin": "https://www.linkedin.com/company/cleveland-biolabs-inc-/"
    },
    "investor_relations": "https://www.clevelandbiolabs.com/investor-relations/",
    "key_executives": [
        {
            "name": "Andrzej B. K. Kaczmarek",
            "position": "CEO"
        },
        {
            "name": "Igor D. Kovalchuk",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "CBLB502"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cleveland BioLabs, Inc. | Innovative Biotechnology Solutions",
        "meta_description": "Explore Cleveland BioLabs, Inc., a leader in biotechnology focused on developing therapies that enhance the body's defenses against cancer and serious diseases.",
        "keywords": [
            "Cleveland BioLabs",
            "Biotechnology",
            "Cancer Treatment",
            "CBLB502",
            "Immunotherapy"
        ]
    },
    "faq": [
        {
            "question": "What does Cleveland BioLabs focus on?",
            "answer": "Cleveland BioLabs focuses on developing innovative therapies to enhance the body's natural defenses against cancer and other serious medical conditions."
        },
        {
            "question": "Where is Cleveland BioLabs headquartered?",
            "answer": "Cleveland BioLabs is headquartered in Buffalo, New York, USA."
        },
        {
            "question": "What is CBLB502?",
            "answer": "CBLB502 is Cleveland BioLabs' lead product candidate designed to protect healthy tissues from radiation."
        },
        {
            "question": "When was Cleveland BioLabs founded?",
            "answer": "Cleveland BioLabs was founded in 2006."
        }
    ],
    "competitors": [
        "ATNM",
        "IMUC",
        "TRIL"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "BMY"
    ]
}